Clinical Trial Update: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Botensilimab (AGEN1181) in advanced melanoma shows the study is ongoing with the status listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Botensilimab (AGEN1181) (Botensilimab)

Snippet

Sponsor: Agenus Inc. | Conditions: Advanced Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING